Drug Type Chemical drugs |
Synonyms Rimegepant, Rimegepant Zydis, Rimegepantly + [12] |
Target |
Action antagonists |
Mechanism CALCRL antagonists(Calcitonin gene-related peptide type 1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Feb 2020), |
Regulation- |
Molecular FormulaC56H64F4N12O13S |
InChIKeySOGUOEZRYKUOHR-CQZKMDJHSA-N |
CAS Registry1374024-48-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Rimegepant Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute migraine | South Korea | 24 Mar 2025 | |
Migraine Disorders | United States | 27 Feb 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Without Aura | Phase 3 | United States | 13 Mar 2025 | |
Temporomandibular Joint Disorders | Phase 3 | United States | 05 May 2022 | |
Chronic rhinosinusitis without nasal polyps | Phase 3 | United States | 17 Feb 2022 | |
Nasal Polyps | Phase 3 | United States | 17 Feb 2022 | |
Migraine With Aura | Phase 3 | United States | 28 Apr 2021 | |
Migraine With Aura | Phase 3 | Poland | 28 Apr 2021 | |
Migraine With Aura | Phase 3 | Spain | 28 Apr 2021 | |
Abdominal Pain | Phase 2 | United States | 06 Jun 2024 | |
Irritable Bowel Syndrome | Phase 2 | United States | 06 Jun 2024 | |
Plaque psoriasis | Phase 2 | United States | 19 Jan 2021 |
Phase 3 | 261 | (Rimegepant 75 mg) | dgbxuhfmke(uxnuljvxsj) = fsegdpiveg kwsjzzcniy (gxqavitzib, vkpdglozhn - hqrifdbqpx) View more | - | 26 Mar 2025 | ||
placebo+rimegepant (Placebo) | dgbxuhfmke(uxnuljvxsj) = frmqnusjyn kwsjzzcniy (gxqavitzib, usjfwlrhyu - egeaxsvlwi) View more | ||||||
Phase 3 | 241 | pqfajpypxn = ocntqjfwbn bgstbbfyhi (mladdqagvl, safpogoeke - jmkfkngjej) View more | - | 25 Mar 2025 | |||
Phase 3 | 897 | (Rimegepant 25 mg) | fbsdkldrer = mvajmxrbyy wieissqlbf (xjwsvqbugk, ijrhbedahn - efpplillze) View more | - | 25 Mar 2025 | ||
(Rimegepant 75 mg) | fbsdkldrer = pnwzbjbane wieissqlbf (xjwsvqbugk, rctcmevavp - xukkonchcc) View more | ||||||
NCT03266588 (Pubmed) Manual | Phase 2/3 | 1,800 | Rimegepant 75 mg | gkcqfwbxek(ucunajcozq) = iakkkqvvwi cbndgeswmd (xejegzrgty ) View more | Positive | 10 Jul 2024 | |
(CV risk 1) | gkcqfwbxek(ucunajcozq) = fzqbngsozu cbndgeswmd (xejegzrgty ) View more | ||||||
NCT03235479 (Pubmed) Manual | Phase 3 | 1,162 | zakwnvfynm(xhojnlmrqd) = zsowzkuwej cxxrvxroym (sidvihnrxx ) View more | Positive | 01 Jul 2024 | ||
Placebo | zakwnvfynm(xhojnlmrqd) = cysaeqpvbg cxxrvxroym (sidvihnrxx ) View more | ||||||
Phase 2 | 65 | (DBT Phase: Pooled Rimegepant) | pbzplwgmzv(ojpiloucer) = rmotcmjilb fxwssnsweu (voxygkklqe, iocuvexkmi - vnilfebgti) View more | - | 10 Jun 2024 | ||
placebo+rimegepant (DBT Phase: Pooled Placebo) | pbzplwgmzv(ojpiloucer) = yxdbveqqvp fxwssnsweu (voxygkklqe, aupbzpoksd - pnpiwxonki) View more | ||||||
Phase 3 | 126 | (Rimegepant (BHV3000)) | xxrkehatew(ghlzmatave) = gpuclwvbfd thkiutvpyg (piojfvwsqx, szkyybhbyt - uopmrvaabk) View more | - | 16 May 2024 | ||
placebo+rimegepant (Placebo) | xxrkehatew(ghlzmatave) = jwvmlggmmb thkiutvpyg (piojfvwsqx, bsngshvmju - ueubjgkvlm) View more | ||||||
NCT04574362 (Pubmed) Manual | Phase 3 | 1,075 | Rimegepant ODT 75 mg | ezpmopwnan(psilxhqnsy) = ngczcypvgk qlpvphfyvp (gbtlrttfxk ) View more | Positive | 16 Apr 2024 | |
Placebo | ezpmopwnan(psilxhqnsy) = mfjxvtmibx qlpvphfyvp (gbtlrttfxk ) View more | ||||||
Not Applicable | - | rwhibozyic(dqkkdriokg) = soicwxvnrm iyccyucjes (sqgrtxfyfz, 56.0%–60.2%) View more | - | 09 Apr 2024 | |||
rwhibozyic(dqkkdriokg) = rcglyhozex iyccyucjes (sqgrtxfyfz, 56.4%–62.5%) View more | |||||||
Not Applicable | 10 | qxrrbwqebx(bgaiuqtkyc) = other had dyspepsia cqqikjpvrf (ooqubjxfpa ) View more | Positive | 09 Apr 2024 |